Halozyme Therapeutics, Inc. $HALO Stake Lessened by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 91.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,153 shares of the biopharmaceutical company’s stock after selling 92,855 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Halozyme Therapeutics were worth $476,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new stake in Halozyme Therapeutics during the 1st quarter worth about $32,000. SVB Wealth LLC acquired a new position in shares of Halozyme Therapeutics in the 1st quarter valued at about $33,000. Brooklyn Investment Group lifted its position in shares of Halozyme Therapeutics by 1,558.1% in the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 670 shares in the last quarter. CWM LLC boosted its holdings in shares of Halozyme Therapeutics by 46.3% during the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 438 shares during the period. Finally, Harvest Fund Management Co. Ltd purchased a new position in Halozyme Therapeutics during the first quarter valued at approximately $89,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 1.6%

Halozyme Therapeutics stock opened at $70.03 on Friday. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $79.50. The company’s fifty day moving average price is $70.27 and its two-hundred day moving average price is $63.21. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The company has a market capitalization of $8.24 billion, a price-to-earnings ratio of 16.03, a PEG ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm’s revenue was up 22.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.27 EPS. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total value of $1,382,600.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at $50,721,994.47. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Nicole Labrosse sold 20,000 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the sale, the chief financial officer owned 24,306 shares of the company’s stock, valued at $1,840,207.26. The trade was a 45.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 110,227 shares of company stock worth $8,028,955 over the last 90 days. Insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on HALO. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Benchmark upped their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. JMP Securities boosted their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 6th. Finally, Citizens Jmp raised their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research note on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.